人工智能在基于计算结构的GPCR药物发现中与物理学相遇
Mayako Michino1,2, Jeremie Vendome3, Irina Kufareva4
1Sanders Tri-Institutional Therapeutics Discovery Institute, New York, NY USA.
概括
人工智能正在为G蛋白结合受体 (GPCRs) 进行基于结构的药物发现进行革命. 人工智能模型增强了命中发现和领先优化,为这些具有挑战性的治疗目标提供了新的策略.
科学领域:
- 药理学和化学信息学
- 计算生物学和药物设计
背景情况:
- G蛋白结合受体 (GPCRs) 是药物标的一个关键类别.
- 基于结构的药物发现 (SBDD) 对于GPCRs在历史上面临着重大挑战.
- 传统的SBDD方法在确定有效的GPCR向治疗方法方面取得了有限的成功.
研究的目的:
- 探索人工智能 (AI) 对GPCR药物发现的变革性影响.
- 详细介绍计算模型在GPCR的命中发现和优化中的应用.
- 为开发和验证该领域预测模型的最佳实践提供指导.
主要方法:
- 对GPCRs人工智能驱动的计算建模的最新进展进行审查.
- 分析AI在加速成功识别和优化流程中的作用.
- 讨论生成和验证预测计算模型的方法.
主要成果:
- 人工智能驱动的计算模型正在显著提高GPCR药物发现的效率.
- 为识别和优化针对GPCRs的候选药物开辟了新的途径.
- 经过验证的预测模型为未来的治疗开发提供了一个有希望的方法.
结论:
- 人工智能代表了解决基于GPCR结构的药物发现复杂性的范式转变.
- 计算模型正在成为推进GPCR向治疗的必不可少的工具.
- 采用最佳实践确保了AI在开发新型GPCR药物的可靠应用.
更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.5K
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
542
相关概念视频
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
G Protein-coupled Receptors
13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K
Protein-protein Interfaces
13.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.4K
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Transducer Mechanism: G Protein–Coupled Receptors
2.5K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.5K
